BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T041143
CREATED:20220805T095510Z
LAST-MODIFIED:20220805T095849Z
UID:34850-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: USA 2022
DESCRIPTION:The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes\, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges\, drug developers will have the opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. Furthermore\, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts\, including the Head of CBER\, on topics including how to handle USP 61/62\, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs\, pharma voices\, investment bodies\, and more on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: www.microbiomeconnectusa.com
URL:https://www.pharmajournalist.com/event/microbiome-connect-usa-2022/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T041143
CREATED:20221024T222603Z
LAST-MODIFIED:20221024T222746Z
UID:35596-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Liquid Biopsy Surveillance & Early Detection Summit
DESCRIPTION:Recognize Disease Hallmarks Earlier for Improved Patient Outcomes \nGain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring\, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access \nIn the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca\, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it\, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development. \nWith technology maturity on the near horizon\, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes. \nAs drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting\, here lies your best opportunity to harness game-changing technologies to define leading stratification\, surrogate endpoint\, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic. \nProviding a path forward for early detection & surveillance to become a widespread patient reality\, unite with 80+ Translational\, Biomarker\, Clinical\, Regulatory\, Precision Medicine\, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention. \nTo know more visit: https://ter.li/0kjtfi
URL:https://www.pharmajournalist.com/event/liquid-biopsy-surveillance-early-detection-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR